Bio News
Takeda has discontinued Phase 2 development of TAK-101, an investigational treatment for celiac disease. The nanoparticle therapy was acquired for $420 million in 2019 but failed to show sufficient efficacy in a Phase 2 trial involving 101 participants. Takeda’s celiac disease pipeline now consists solely of the TG2 inhibitor TAK-227.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
